Effect of arabinoxylan intake on plasma acetate concentration (pilot study)

Effect of arabinoxylan intake on plasma acetate concentration (pilot study) - Effect of arabinoxylan intake on plasma acetate concentration (pilot study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000044547

Enrollment

Registered

2021-06-17

Start date

2021-06-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

serial containing arabinoxylan intake (80g, once)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects having an ability to understand study purpose and detail with voluntary written informed consent 2. Subjects having arabinoxylan assimilating bacteria

Exclusion criteria

Exclusion criteria: 1. Subjects taking antibiotics or any drugs affect on microbiota 2. Subjects with food allergies, especially for wheat and/or milk 3. Pregnant women 4. Subjects participating or willing to participate in other clinical studies 5. Subjects judged as unsuitable for the study participant from other reasons

Design outcomes

Primary

Measure	Time frame
Tmax value of acetate after arabinoxylan intake	—

Countries

Japan

Contacts

Public ContactChiaki Kaga

Yakult Honsha Co., Ltd Yakult Central Institute

chiaki-kaga@yakult.co.jp042-577-8960

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026